1
Return

Narcolepsy type 1 following immune checkpoint inhibitor therapy for metastatic melanoma

delete2026-04-06
delete1
PRE
AI
H
Hii, Su *
K
Kee, Kirk
DOI：10.1136/bcr-2026-272044delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Narcolepsy is a rare disorder of central hypersomnolence which is often under-recognised owing to a variable clinical phenotype. Narcolepsy type 1 (NT1) is caused by loss of hypothalamic hypocretin (orexin) secreting neurons, which function to maintain wakefulness. There is strong evidence that NT1 is an immune-mediated disorder associated with the class II human leucocyte antigen DQB1*06:02 allele. Immune checkpoint inhibitors have revolutionised the treatment of many cancers; however, through their mechanism of action, they are associated with immune-related adverse effects. We describe a complex case of NT1 following ipilimumab and nivolumab exposure for management of metastatic melanoma.
Keywords:
Sleep disorders (respiratory medicine)
Immune Checkpoint Inhibitors

Journal

BMJ Case Reports cover
BMJ Case Reports
IF:
0.5
Papers:
929
Citations:
1.2W

Organization

M
melbourne health
Scholars:
6.9K
Papers: 5.2K
Citations: 9
Cited Papers

Cited Papers

Citing Papers

Citing Papers